| Literature DB >> 31636787 |
Daniel Patschan1, Katrin Schwarze2, Elvira Henze2, Johanna Charlotte Hoffmann2, Susann Patschan1, Oliver Ritter1, Gerhard Anton Muller2.
Abstract
BACKGROUND: Acute kidney injury (AKI) significantly worsens the prognosis of hospitalized patients. Diabetes mellitus (DM) affects a growing number of individuals in the western world. DM subjects are at a higher risk for acquiring AKI during the stay at the hospital. The current study intended to quantify serum levels of specific immunomodulatory cytokines in diabetic mice suffering from AKI.Entities:
Keywords: Acute kidney injury; Diabetes mellitus; Insulin; Systemic inflammation
Year: 2019 PMID: 31636787 PMCID: PMC6785280 DOI: 10.14740/jocmr3852
Source DB: PubMed Journal: J Clin Med Res ISSN: 1918-3003
Figure 1Methodical approach in the current study. Insulin-dependent diabetes mellitus was induced in male C57/Bl6N mice by IP injection of streptozotocin for 5 consecutive days. Blood glucose testing was performed at day 7 after the first injection. Six weeks later, animals underwent bilateral renal ischemia (ischemia reperfusion injury), followed by systemic administration of native or preconditioned syngeneic murine PACs. Cytokine analysis was performed 2 days (48 h) later. IP: introperitoneally; PAC: proangiogenic cell.
Figure 2Serum cytokine levels at 48 h after ischemia-reperfusion injury in non-diabetic and diabetic mice. IRI: ischemia reperfusion injury; STZ: streptozotocine; PAC: proangiogenic cell. The symbols indicate significant differences (P < 0.05) in comparison to certain groups: * as compared to “Control”; ° as compared to “IRI”; + as compared to “IRI STZ PACs” in I and K and to “IRI STZ” in L and to “IRI” in R; # as compared to “IRI STZ PACs” in A and to “IRI” in B, E, L, and M (all data as mean ± SEM).